LSD1-IN-24

LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .


Cat. No.: EX-A17512	Purity: >98%

	Chemical structure of LSD1-IN-24

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	406	in_stock
100mg	641	in_stock
250mg	1303	in_stock
500mg	2071	in_stock
1g	3343	in_stock
2g	5352	in_stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	4734-59-2
Purity	>98%
Formula	C18H20N2OS
Mol Weight	312.429
Color	Pale purple to purple
State	Solid
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1].Singh V, et al. Generation of Phenothiazine with Potent Anti-TLK1 Activity for Prostate Cancer Therapy. iScience. 2020;23(9):101474. Published 2020 Aug 20. [2].Dai XJ, et al. Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells. J Med Chem. 2023;66(6):3896-3916.
CoA	CoA of LSD1-IN-24

Smiles:	N1(CCN2C3=C(SC4=C2C=CC=C4)C=CC=C3)CCOCC1


		Search